A moderately differentiated neuroendocrine carcinoma of the larynx is described. Although the patient had normal serum calcitonin level 36 months before, its level was elevated at the time the neck node was removed. This study supports the hypothesis that a diagnosis of calcitonin-producing neuro-endocrine tumor of the larynx with increased plasma calcitonin is possible and should be considered to avoid unnecessary thyroidectomy.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1177/030089169307900315 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
STC1 encapsulated in small extracellular vesicles from laryngeal squamous cell carcinoma cells induces CD8 T cell dysfunction by reprogramming tumor-associated macrophages into M2-like macrophages.
Cancer Immunol Immunother
January 2025
Department of Otorhinolaryngology-Head and Neck Surgery, The Second Affiliated Hospital of Harbin Medical University, No. 246 Xuefu Road, Nangang District, Harbin, 150001, Heilongjiang Province, China.
Background: Tumor-derived small extracellular vesicles (sEVs) play an essential role in reprogramming the tumor microenvironment. Metabolic reprogramming is an essential prerequisite for M2 polarization of tumor-associated macrophages (TAMs). This M2 phenotype is closely related to the immune dysfunction of CD8 T cells and subsequent tumor progression.
View Article and Find Full Text PDFEpigenetic silencing of promotes laryngeal squamous cell carcinoma development by inhibiting the Hippo pathway.
Oncol Rep
February 2025
Department of Otolaryngology Head & Neck Surgery, The First Hospital, Shanxi Medical University, Taiyuan, Shanxi 030001, P.R. China.
Laryngeal squamous cell carcinoma (LSCC), which represents a significant proportion of head and neck squamous cell carcinoma cases, is often diagnosed at advanced stages, underscoring the urgent need for effective biomarkers and therapeutic targets. Junctional adhesion molecule 3 () is implicated in various types of cancer; however, its role in LSCC remains unclear. Therefore, the present study aimed to investigate the epigenetic regulation and tumor‑suppressive functions and mechanisms of in LSCC.
View Article and Find Full Text PDFDCUN1D5 is a prognostic biomarker and correlated immune infiltrates and glycolysis in lung adenocarcinoma.
Sci Rep
January 2025
Department of Thoracic Surgery, Affiliated Hospital of Chengde Medical College, Chengde, 067000, Hebei, China.
DCUN1D5 is up-regulated and promotes tumor progression in many cancers such as laryngeal squamous cell carcinoma and breast cancer, but the expression of DCUN1D5 in lung adenocarcinoma and its molecular mechanism are not clear. The differences of DCUN1D5 expression between lung adenocarcinoma and normal tissues were compared by TCGA, GEO and UALCAN databases, and the relationship between DCUN1D5 expression and clinicopathological features of patients was analyzed. The diagnostic and prognostic value of DCUN1D5 in patients with LUAD was analyzed by TCGA, GEPIA and Kaplan-Meier Plotter database.
View Article and Find Full Text PDFDedifferentiation of a Chondrosarcoma of the Larynx: A Case Report.
Head Neck
January 2025
Department of Otolaryngology - Head and Neck Surgery, Loyola University Medical Center, Maywood, Illinois, USA.
Background: Chondrosarcomas of the larynx, relatively rare tumors with low grade pathology in approximately 95% of cases, can most often be managed with conservation laryngeal procedures. Dedifferentiated chondrosarcomas are much more rare and aggressive requiring more aggressive surgical extirpation.
Methods: A patient underwent three debulking procedures for a laryngeal chondrosarcoma Grade I/II histologically over a 2.
AKR1B10 and digestive tumors development: a review.
Front Immunol
December 2024
Medical School, Hunan University of Chinese Medicine, Changsha, Hunan, China.
Aldo-keto reductase family 1 member B10 (AKR1B10) is a member of the AKR1B subfamily. It is mainly found in cytoplasm, and it is typically expressed in the stomach and intestines. Given that its expression is low or absent in other tissues, AKR1B10 is a potential diagnostic and therapeutic biomarker for various digestive system diseases.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!